Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc) is designed to be expressed as a homodimer, which has 2+2 antigen-binding valency. This format consists of one Fc region and two tandem scFv fragments, in which the anti-CD37/CD64 tandem scFv is fused to the Fc domain. The engineered fragment format is used to extend the half-life. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.